Post-COVID syndrome

Research Underway To Treat COVID-19 Long Hauler Syndrome

In this article, UF Innovate | Sid Martin Biotech resident client Neobiosis founder Ian White explains how his company is using regenerative medicine to develop products to treat coronavirus long hauler syndrome. (Note: the University of Florida Innovate Center mentioned in the story should be UF Innovate | Sid Martin Biotech.)

New Resident Client at Sid Martin Biotech to Pave Way for Post-COVID Therapy, Regenerative Medicine Research

The inflammation COVID-19 patients suffer during and post-COVID-19 infection (AKA "Post-COVID Syndrome") will be one of many focuses of a new resident client that recently joined the UF Innovate | Sid Martin Biotech, the world-recognized leader in biotechnology incubation. Neobiosis, which produces regenerative tissues, cells, and extracellular vesicles for research and clinical trials to help the body heal itself—without surgery—will operate a laboratory at the biotech center, located in Alachua.